Ice inhibiting peptides

Details Ice inhibiting peptides Ice inhibiting peptides

1999-07-01

2002-04-30

Celsa, Bennett (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S012200, C530S324000, C530S325000, C530S326000

Reexamination Certificate

active

06380162

ABSTRACT:

CROSS REFERENCE TO RELATED APPLICATION
The present application is the national stage under 35 U.S.C. 371 of PCT/EP96/04738, filed Oct. 31, 1996.
FIELD OF THE INVENTION
The present invention relates to a peptide capable of binding to ICE and/or to enzymes of the ICE family, which peptide consists essentially of the amino acid sequence of SEQ ID NO:1, in which Xaa is selected between Asp and Ala, optionally containing one or more amino acids at its N-terminal and/or C-terminal end.
It also relates to the use of the above peptide, for the preparation of pharmaceutical compositions active in pathologies requiring ICE inhibition and/or inhibition of enzymes of the ICE family.
BACKGROUND OF THE INVENTION
ICE (Interleukin-1&bgr;-Converting Enzyme) is a heterodimeric cysteine protease that has been recently purified and cloned (1). Interleukin-1&bgr; (IL-1&bgr;) is synthesised as an inactive 33 kDa or 31 kDa precursor (pIL-1&bgr;); the fully active 17.5 kDa mature form of IL-1&bgr; begins at Ala
117
and seems to result from processing between Asp
116
and Ala
117
(2,3). IL-1&bgr; precursor protein is, therefore, cleaved by ICE in the mature and biologically active form.
ICE activity has been identified in monocytes and THP1 cells, which cleave pIL-1&bgr; at Asp
116
-Ala
117
as well Asp
27
-Gly
28
to yield products of 17.5 kDa and 28 kDa, respectively (3,4). Cleavage at each site is dependent on aspartic acid in the P1position (4,6,7).
It is becoming apparent that cysteine proteases related to the
Caenorhabditis elegans
cell death protein ced-3 represent the effector components of the apoptotic machinery. ICE was the first described homologue of CED-3 and it is known that overexpression of ICE of CED-3 in Rat-1 fibroblasts induced apoptosis (8). Further studies also suggest that proteases of the ICE family may play an important role in the apoptotic mechanism.
ICE seems to be a pIL-1&bgr; specific processing enzyme, because it does not cleave IL-1&agr; or several other proteins containing many Asp-X bonds.
Interleukin IL-1&agr; and IL-1&bgr; are pleiotropic cytokines, which, although their sequences show scarce analogy, exert a variety of similar effects on different tissues and act on many human pathologies, in particular on the immunitary response of the organism and on inflammatory processes (9). Both proteins have a molecular weight of about 17.5 KDa and are previously synthesised as precursor molecules of larger size having a molecular weight of about 31 KDa.
IL-1s are potent inflammatory and pyrogenic cytokines that normally have beneficial effects but can also have extremely unhealthy effects for the organism. They can, for example, participate in the pathogenesis of symptoms of the autoimmune pathologies like systemic lupus erithematosus and, in particular, they are involved as mediators to provoke damages to tissues as for example in rheumatoid arthritis.
Many of the biological effects of IL-1 are similar to those that can be observed during a septic event. Recent studies demonstrated that the intravenous administration of IL-1 in doses from 1 to 10 ng/kg gives rise to fever, sleepiness, anorexia, generalised myalgia, arthralgia and cephalea.
Since IL-1s have pleiotropic biological activities, many of which influence negatively the organism, the powerful effects of IL-1 should be under strict physiological control.
IL-1 synthesis is inhibited by anti-inflammatory cytokines, prostaglandins and glucocorticoids and the existence of multiple levels of inhibition of IL-1 points to the necessity of a strict control of this mediator.
There are two types of IL-1 receptors named IL-1RI and IL-1RIL IL-1RII is a non-signalling IL-1 binding molecule which acts as a regulated decoy target for IL-1 (10-12).
An antagonist polypeptide for the receptor of IL-1 has been described up to now: the third known component until today of the family of the receptor-binding proteins is the antagonist for the IL-1 receptor (IL-1ra) (13-15). All three components (IL-1&agr;, IL-1&bgr;, IL-1ra) recognise and bind to the same receptor on cell surface (IL-1R); IL-1&agr; and IL-1&bgr; binding to IL-1R transmit a signal, whilst IL-1ra does not.
IL-1ra is a polypeptide which binds IL-1RI, and with less affinity IL-1RII, without any agonistic activity. IL-1ra production is induced in different cellular types, including mononuclear phagocytes, polymorphonuclear cells (PMN) and fibroblasts, by IgG. cytokines and bacterial products.
Until now two molecular forms of IL-1ra have been identified and cloned: 1) secreted IL-1ra (sIL-1ra) contains a classical leader sequence of 25 amino acids giving a mature protein of 152 amino acids; 2) intracellular IL-1ra (icIL-1ra) lacks a leader sequence thus allowing to predict that this protein remains intracellular.
sIL-1ra and icIL-1ra are generated from the same gene. icIL-1ra transcripts originate from an alternative starting site and from the splicing of a first alternative exon into an internal splice acceptor site located in the first exon of sIL-1ra. The predicted proteins are thus identical except in the NH
2
ends, where the first 21 amino acids of sIL-1ra are substituted by four amino acids in icIL-1ra.
Expression of transcripts encoding sIL-b
1
ra and icIL-1ra is differently regulated. The biological significance of icIL-1ra is still unclear.
Considering that IL-1 is involved in pathogenesis of many diseases it is evident the need of having available medicaments useful to limit the unhealthy effects of IL-1.
A new molecular form of icIL-1ra has recently been identified and cloned (16 and PCT/EP95/04023). This molecule is generated by the in frame insertion of a new 63 bp exon between the first and the second exons of the icIL-1ra specific form. This new transcript has been found to be expressed in fibroblasts, keratimocytes, activated monocytes and polymorphonuclear cells. Expression in COS cells revealed that this new molecule is mostly intracellular and has a molecular weight of approximately 25 kDa in SDS-PAGE. Such new molecule has been called icIL-1ra type II (icIL-1raII). Considering that icIL-1raII is an intracellular protein as well as ICE, the Applicant has also tested the ability of icIL-1raII to inhibit ICE activity. The results are reported in the Examples of this patent application and show that icIL-1raII inhibits ICE activity.
DESCRIPTION OF THE INVENTION
The main object of the present invention is to provide new peptides capable of binding to ICE, thus blocking the production of the active form of IL-1&bgr; and/or, more generally, capable of binding to enzymes of the ICE family, thus blocking the activity of such enzymes. So the present invention relates to a peptide capable of binding to ICE and/or to enzymes of the ICE family, which peptide consists essentially of the amino acid sequence of SEQ ID NO:1, in which Xaa is selected between Asp and Ala, as specifically reported in SEQ ID NO:2 or 3. Optionally, the peptide also contains one or more amino acids at the N-terminal and/or the C-terminal end. Therefore, the peptide of the invention can be 19-40, preferably 19-25 amino acids long.
In particular, according to one embodiment of the invention, the peptide consists essentially of the amino sequence of SEQ ID NO:4 or 5.
A non-limiting list of cysteine proteases of the ICE family includes: CED-3 (17), Nedd-2/ICH-1 (18, 19), Yama/CPP-32/Apopain (20, 21, 22), Tx/ICH-2/ICE rel-II (23, 24, 25), ICE rel-III (25), Mch-2 (26), ICE-LAP3/Mch-3/CMH-1 (27, 28, 29), ICE-LAP-6 (30) and FLICE/MACH (31, 32).
Another object of the present invention is to provide the peptide in substantially purified form in order to be suitable for use in pharmaceutical compositions as active ingredient in pathologies that require ICE inhibition and/or inhibition of enzymes of the ICE family.
Examples of pathologies in which the new antagonist according to the invention can be advantageously used for prophylactic, therapeutic or diagnostic uses are lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. Specific examples include: rheumatoid arthr

Affiliated with

Also associated with

Rating

Ice inhibiting peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ice inhibiting peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ice inhibiting peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2858990